In a small trial of 18 rectal cancer patients consuming the same drug, the cancer vanished in every single patient, undetectable by physical exam, endoscopy, PET scans or M.R.I. scans.
"I believe this is the first time this has happened in the history of cancer,"
- Dr. Diaz, of Memorial Sloan Kettering Cancer Center
On average, one in five patients have some sort of adverse reaction to drugs like the one the patients took, dostarlimab, known as checkpoint inhibitors.<
The medication was given every three weeks for six months and cost about $11,000 per dose.
The study was funded by a small biotechnology firm, Tesaro, which was later bought by GlaxoSmithKline.